TALIS BIOMEDICAL CORP (TLIS)
US87424L2079 - Common Stock
Overall TLIS gets a fundamental rating of 3 out of 10. We evaluated TLIS against 192 industry peers in the Health Care Equipment & Supplies industry. TLIS has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, TLIS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year TLIS has reported negative net income.
In the past year TLIS has reported a negative cash flow from operations.
In the past 5 years TLIS reported 4 times negative net income.
In the past 5 years TLIS always reported negative operating cash flow.
1.2 Ratios
TLIS has a Return On Assets of -70.38%. This is in the lower half of the industry: TLIS underperforms 78.13% of its industry peers.
TLIS's Return On Equity of -92.54% is on the low side compared to the rest of the industry. TLIS is outperformed by 67.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.38% | ||
| ROE | -92.54% | ||
| ROIC | N/A |
ROA(3y)-61.64%
ROA(5y)-53.9%
ROE(3y)-73.74%
ROE(5y)-75.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TLIS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLIS has about the same amout of shares outstanding than it did 1 year ago.
TLIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
TLIS has an Altman-Z score of -7.95. This is a bad value and indicates that TLIS is not financially healthy and even has some risk of bankruptcy.
TLIS has a worse Altman-Z score (-7.95) than 76.04% of its industry peers.
There is no outstanding debt for TLIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.95 |
ROIC/WACCN/A
WACC9.97%
2.3 Liquidity
A Current Ratio of 10.60 indicates that TLIS has no problem at all paying its short term obligations.
TLIS has a Current ratio of 10.60. This is amongst the best in the industry. TLIS outperforms 91.67% of its industry peers.
A Quick Ratio of 10.60 indicates that TLIS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.60, TLIS belongs to the top of the industry, outperforming 94.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.6 | ||
| Quick Ratio | 10.6 |
3. Growth
3.1 Past
The earnings per share for TLIS have decreased strongly by -131.19% in the last year.
TLIS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.41%.
The Revenue has been growing slightly by 6.52% on average over the past years.
EPS 1Y (TTM)-131.19%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q41.36%
Revenue 1Y (TTM)-59.41%
Revenue growth 3Y6.52%
Revenue growth 5YN/A
Revenue growth Q2Q-82.5%
3.2 Future
Based on estimates for the next years, TLIS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.84% on average per year.
Based on estimates for the next years, TLIS will show a very strong growth in Revenue. The Revenue will grow by 37.05% on average per year.
EPS Next Y48.33%
EPS Next 2Y27.51%
EPS Next 3Y15.84%
EPS Next 5YN/A
Revenue Next Year-60.4%
Revenue Next 2Y-41.42%
Revenue Next 3Y37.05%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TLIS. In the last year negative earnings were reported.
Also next year TLIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TLIS's earnings are expected to grow with 15.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.51%
EPS Next 3Y15.84%
5. Dividend
5.1 Amount
TLIS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TALIS BIOMEDICAL CORP
NASDAQ:TLIS (5/3/2024, 7:22:01 PM)
9.15
+0.05 (+0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.65M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.38% | ||
| ROE | -92.54% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.6 | ||
| Quick Ratio | 10.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-131.19%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y48.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-59.41%
Revenue growth 3Y6.52%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y